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INTRODUCTION
Cathepsins have a vital role in mammalian cellular 
turnover. In living organisms their activity depends 
on a delicate balance of expression, targeting, zymo-
gen activation, inhibition by protein inhibitors and 
degradation. They constitute a large family which is 
involved in various cellular processes such as MHC 
antigen presentation, protein degradation, hormone 
regulation and TNF induced apoptosis1. Cathepsins’ 
family is composed of at least fifteen discrete mem-
bers, which characterized by their structure and sub-
strate specificity1,2. Based on these properties, cathep-
sins are divided into three different groups: the serine 
proteases (cathepsins A and G), the aspartic proteases 
(cathepsins D and E) and the cysteine proteases (ca-
thepsins B, C, F, H, K, L, O, S, U, W and X). These 
proteases are found inside the cellular organelles 
mainly in lysosomes and peroxisomes, as inactive 
proenzymes3. However, recent studies have shown 
that active cathepsins are located in other cellular 
compartments, such as nucleus, cytoplasm and plasma 
membrane, where they contribute in protein turnover 
and degradation of polypeptides. It was shown that the 
catalytically active variants of cathepsin L localized in 
the nucleus play a role in the regulation of cell-cycle 
progression and the proteolytic processing of the N-
terminus of the histone H3 tail.
Following a cell death signal, cathepsins are re-
leased outside the cell and trigger the degradation of 
the extracellular matrix and subsequent cell apopto-
sis4,5,6,7.
On the other hand, cathepsins participate in path-
ological and inflammatory processes including Al-
zeimer’s disease and tumor development and inva-
sion. Increased cathepsins’ expression in cancer cells 
causes tumor cell growth, invasion, and metastasis5 
while the precise role of each cathepsin in carcinogen-
esis remains unclear. Promising targets for anticancer 
therapy seem to be cathepsins B, C, H, L, S and X/Z. 
Τhe levels of these cathepsins are elevated in cancer 
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cells and cells involved in angiogenesis. Cathepsins H 
and L are overexpressed in cancer cells only, in con-
trast to cathepsins B, C, S and X/Z, which are also 
found to be overexpressed in non-malignant cells in 
tumors. As Cathepsin L has been studied most thor-
oughly but yet their functions are still not well-defined 
and as there is growing evidence that the expression 
of cathepsin H is increased in malignant diseases in-
cluding breast, colorectal and prostate carcinoma6, we 
decided to estimate the expression levels of the two 
cysteine cathepsins H and L in human colon cancer 
tissue and to correlate the findings to the grade of this 
malignancy. 
MATERIALS AND METHODS
Tissue sample collection
The study comprised 74 patients with colorectal can-
cer (CRC), who underwent colorectal resection in 
Theagenio Cancer Hospital of Thessaloniki, 35 males, 
about 69 years old and 39 females, about 68,9 years 
old. Patients were not undergoing chemotherapy, ra-
diotherapy, or any other adjuvant therapy for CRC, 
before the colorectal resection. Clinical data of the 
patients and histology of tumors were registered ac-
curately. In addition, all patients were monitored after 
surgery. 
The resected tumors have been sub grouped ac-
cording to their location (colon cancer, n = 48; rectal 
cancer, n = 26), but mainly they have been histologi-
cally classified according to Astler-Coller staging sys-
tem: in stage A the tumor has been confined to mucosa 
(n = 3); in stage B1 the tumor has extended into mus-
cularis propria but it hasn’t penetrated it and nodes 
haven’t been involved (n = 13); in stage B2 the tumor 
has penetrated muscularis propria, but nodes haven’t 
been involved (n = 18); in stage C1 the tumor has ex-
tended into muscularis propria, it hasn’t penetrated 
through, but nodes have been involved (n = 11); in 
stage C2 the tumor has penetrated muscularis pro-
pria, and nodes have been involved (n = 15); finally, 
in stage D the tumor has been associated with distant 
metastases (n = 14) (Table 1).
The samples have been taken from the resected tis-
sues. The malignant samples have been collected from 
different areas of the lesion that was macroscopically 
evident, as well as from the adjacent normal tissue 
(controls). As normal tissue has been characterized 
the tissue where there haven’t been macroscopically 
dead or hemorrhagic foci. Presence or absence of le-
sion was confirmed histopathologically in all cases ac-
cording to current guidelines. After the collection, all 
tissue samples have been frozen in liquid nitrogen and 
stored at -80oC until used. 
ELISA assay for quantitative detection of cathepsins 
H and L
Prior to assay, the frozen samples have been brought 
to room temperature, washed in isotonic solution of 
sodium chloride (CAS No: 8028-77-1), cut into piec-
es, weighed and homogenized in 4°C with lysis buffer 
[50 mM HEPES (CAS No: 7365-45-9) pH 7.4, 5 mM 
CHAPS (CAS No: 75621-03-3), 5 mM 1 DTT (CAS 
No:7634-42-6)], in proportion: 1 gr tissue/10 ml ly-
sis buffer. The homogenized tissues have remained at 
-20°C for 24 hours and then they have been centri-
fuged at 20000 g for 15 min at 4°C. Supernatants (10 
μl per well) have been used for quantitative detection 
of cathepsins H and L by enzyme-linked immunosor-
bent assay.
Anti-human cathepsin-H and cathepsin-L coat-
ing antibodies have been adsorbed onto microwells. 
Aliquots of supernatants (10μl per well) have been 
bound to corresponding adsorbed antibodies. Biotin-
conjugated anti-human cathepsin-H and cathepsin-L 
antibodies have been added and bound to correspond-
ing cathepsin captured by the first antibodies. After 
Table 1. Clinical characteristics of the colorectal cancer pa-
tients included in the study.
Patients Charasteristics Data
Number of patients 74
Mean Age ± 69 years
Male 35
Female 39
Period 2009-2010
Tumour Site Colon and rectum
Colon 48
Rectum 26
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incubation unbound biotin-conjugated antibodies 
have been removed during a wash step and strepta-
vidin-HRP has been added and bound to the biotin-
conjugated anti-human antibodies. Following incuba-
tion unbound streptavidin-HRP has been removed by 
washing and substrate solutions reactivated with HRP 
has been added to the wells. Colored products have 
been formed in proportion to the amount of cathep-
sins present in the samples. The reactions have been 
terminated by addition of 100μl 1M phosphoric acid 
to each well. A spectrofluorometer microplate reader 
(Perking Elmer LS 50 B, using illumination at 440 
nm-measuring emission at 370 nm) has been used to 
measure the absorbance of the ELISA assay at 450 
nm. Tree standard curves have been prepared from 
standard dilutions of the two human cathepsins (H and 
L) and the concentrations of corresponding cathepsins 
of the samples have been determined in ng/mg ho-
mogenated tissue. 
RESULTS
The Graphs 1 and 2 show respectively the expression 
(ng/mg homogenated tissue) of cathepsins H and L in 
human colon cancer tissues. Each graph presents the 
expression of corresponding cathepsin in the tissues 
of the cancerous stages B1, B2, C1, C2 and D and 
of their adjacent normal tissues (controls). The bars 
of B1 stage illustrate the mean value of the expres-
sion of the corresponding cathepsin from 13 differ-
ent patients, the B2 bars have been created from the 
mean value of the expression of the corresponding 
cathepsin from 18 different patients, the C1 bars is 
the mean value of the expression of the correspond-
ing cathepsin from 11 different patients, the C2 bars 
become from the mean value of the expression of the 
corresponding cathepsin from 15 different patients 
and the D bars show the mean value of the expres-
sion of the corresponding cathepsin from 14 differ-
ent patients. The expressions of these two cathepsins 
in all cancerous tissues have been found significantly 
higher than those of the controls.. Cathepsin H has 
been estimated statistically significant increased in all 
the malignant stages compared to that of the adjacent 
normal tissues and as the malignancy has proceeded, 
the elevation has being higher as following: 155%, 
160,71%, 193,19%, 208,20% and 204,44% in stages 
B1, B2, C1, C2 and D respectively than the adjacent 
normal tissues. Between the two investigated prote-
ases cathepsin L has showed the highest increase in all 
stages of malignancy, which was 246,42% in stage B1, 
213,99% in stage B2, 206,95% in stage C1, 218,52% 
in stage C2 and 261,03% in stage D, compared to the 
normal adjacent tissues. 
Statistical Analysis
Student’s t-test and one-way ANOVA test were per-
formed for the statistical evaluation of cathepsins 
Figure 1. Comparison of the expression (ng/ mg) of ca-
thepsin H in colon cancer patients vs controls L in different 
stages (B1, B2, C1, C2, D) of colon cancer. The data are 
shown as mean ± SD of the samples from each group.
Figure 2. Comparison of the expression (ng/ mg) of cathep-
sins L in colon cancer patients vs control L in different stag-
es (B1, B2, C1, C2, D) of colon cancer.The data are shown 
as mean ± SD of the samples from each group. 
4 Aristotle University Medical Journal, Vol. 40, Issue 2, June 2013
H and L expression, in order to determine whether 
any values deviated significantly from the controls 
(p < 0,01). Results were given as mean value of ex-
pression (ng/ml homogenated tissue ) ± standard de-
viation (SD). All statistical analyses were conducted 
using the GraphPad 5,1 statistical software package 
(GraphPad, Europe). 
DISCUSSION
As cancer continues to be one of the most serious 
health issue and colorectal cancer (CRC) the most 
common gastrointestinal cancer in the Western world 
causes of cancer-related death, there is a great need 
for searching of sensitive and specific markers of the 
disease. Proteases have been suggested by several re-
searchers as tumor markers in CRC8,9. 
Clear evidence that cysteine cathepsins aren’t 
only lysosomal proteases and that they have also 
non-lysosomal/endosomal roles implicates them in 
an unimaginable number of biological processes in-
volving the invasion and the migration of cancerous 
cells, but also proliferation, apoptosis and angiogen-
esis that characterize the malignant tumours10. Loss of 
cell–cell and cell–matrix adhesion and degradation of 
extracellular matrix (ECM) components are involved 
in invasion and migration11. Cysteine cathepsins can 
be expressed at the cell surface and secreted into the 
extracellular space, where they can degrade compo-
nents of the ECM and remodel the microenvironment 
of tumour processes. In addition, they may play roles 
in the regulation of the action of certain growth fac-
tors, growth factor-binding proteins and growth factor 
receptors, vital participants in human colorectal can-
cer growth.12,13,14,15 On the other hand cysteine cathep-
sins could contribute in tumour progression, affecting 
intracellular tumorigenic processes, as programmed 
cell death16. 
Cathepsin B is the first cathepsin that has been 
demonstrated to be linked to cancer 30 years ago5. 
Since then it has been found to be expressed in the 
vast majority of colon cancers and adenoma. Other 
investigators have revealed that cathepsins B, C, S 
and X/Z overexpress also in non-malignant cells in 
tumours, while overexpression of cathepsins H and L 
has been indentified in cancer cells only14,17 ,18. 
As it is obvious, the conclusions of the investiga-
tion about the precise biological role of cysteine ca-
thepsins in CRC do not coincide. On the other hand 
numerous clinical reports and results from experimen-
tal works have supported that cysteine cathepsins H 
and L, play a crucial role in both tumour progression 
and invasion18,19 ,20 , but none of them has investigated 
these two proteases concomitantly in the same malig-
nant tissue, using the same assay method and compar-
ing with the same adjacent normal tissue. Therefore 
we were determined to carry out the present study. 
Cathepsin H influences several important tumori-
genic processes including degradation of the extracel-
lular matrix, proteolytic processing of chemokines 
and activation of other enzymes. Numerous clinical 
studies have reported correlations between elevated 
cathepsin H levels and malignant progression how-
ever its specific functions in tumour development and 
progression is not fully understood.21,22,23 Gocheva 
et al have demonstrated for the first time the impor-
tant tumour-promoting role for cathepsin H in vivo 
using a mouse model of human cancer21. They have 
found that deletion of cathepsin H action in crossed 
cathepsin H-deficient mice with the RIP1-Tag2 model 
of pancreatic islet carcinogenesis has significantly 
impaired angiogenic switching of the pre-malignant 
hyperplastic islets and resulted in a reduction in the 
subsequent number of tumours that formed.24,25 When 
Schweiger et al. have measured cathepsin H in preop-
erative sera from 324 patients with colorectal cancer 
by ELISA they have found that its level was signifi-
cantly increased and that there was a weak association 
of cathepsin H levels with patient age but not with 
stage (Astler-Coller), sex or the level of carcinoem-
bryonic antigen (CEA)26 . According to these findings 
and to the results of the survival analysis Schweiger et 
al have concluded that the prognostic information and 
the role during the malignant progression of cathepsin 
H differed from those of the related cathepsin L26. In 
the present work the expression of CRC cathepsin H 
has been estimated statistically significant increased 
(P<0,01) in all the malignant stages compared to 
that of adjacent normal tissues and the elevation has 
been increased as the malignancy proceeded (155%, 
160,71%, 193,19%, 208,20% and 204,44% in stages 
B1, B2, C1, C2 and D respectively). This last finding 
testifies the participation of cathepsin H in tumour de-
velopment and progression and its different behaviour 
as cancer proceeds, in comparison to cathepsin L. 
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The expression of cathepsin L has presented the 
highest increase in all malignant stages. Specifi-
cally the expression of this cathepsin has been esti-
mated 246,42% in B1 stage, slightly degreased in B2 
(213,99%), C1 (206,95%) and C2 (218,52%) stages, 
but slightly elevated (261,03%) in stage D, compared 
to the adjacent physiological tissues. As the differ-
ences among the cathepsin L expression of stages B2, 
C1 and C2 have been negligible, we would agree with 
Herszényi L. et al.27 According to them cathepsin L 
may be involved in the progression from premalig-
nant colorectal adenoma into CRC. Nevertheless 
our results about cathepsin L are in agreement with 
the findings that have been referred in the review of 
Jacqueline Lankelma et al.11 They have evaluated the 
state of affairs concerning cathepsin L as a possible 
target in cancer treatment, as its activity has exclu-
sively been increased in malignant cells, in contrast to 
that of other cathepsins. 
Our parallel investigation about the expression 
levels of cysteine cathepsins H and L in the superna-
tant of colon cancer tissue from 74 patients indicat-
ed that these two cathepsins of all malignant tissues 
presented significant higher expressions’ values than 
those of the corresponding controls. Between the two 
investigated proteases, cathepsin L showed the high-
est increase in all the malignant stages, although the 
expression of cathepsin H increased significantly as 
malignancy progressed. So these data which are in 
agreement with the results of significant, correspond-
ing researches, could suggest that the expression of 
cysteine proteases H and L could be of critical value in 
the diagnosis and progression of colon cancer.
ΠΕΡΙΛΗΨΗ: Οι καθεψίνες, ως πρωτεάσες, ρυθμίζουν σημαντικό αριθμό φυσιολογικών βιολογικών διεργασιών, ενώ δι-
αδραματίζουν επίσης πρωταγωνιστικό ρόλο τόσο στην ανάπτυξη του καρκίνου, όσο και στη μετάσταση του. Σκοπός της 
μελέτης μας ήταν κατ’ αρχή να συγκριθούν τα επίπεδα έκφρασης των καθεψίνων Η και L στο υπερκείμενο ομογενοποιημένου 
καρκινικού ιστού παχέος εντέρου από 74 ασθενείς, με την έκφραση των ίδιων ενζύμων από το υπερκείμενο αντίστοιχων 
φυσιολογικών ιστών, γειτνιαζόντων με τους καρκινικούς, και δεύτερον να συσχετιστούν τα αποτελέσματά αυτά με το βαθμό 
κακοήθειας της νόσου. Οι δραστικότητες των καθεψινών Η και L, οι οποίες προσδιορίστηκαν με τη μέθοδο ELISΑ, όλων 
των καρκινικών ιστών παρουσίασαν τιμές σημαντικά υψηλότερες συγκρινόμενες με τις τιμές των αντίστοιχων φυσιολογι-
κών ιστών. Συγκεκριμένα, η έκφραση της καθεψίνης H παρουσίαζε σημαντική αύξηση, καθώς αυξάνονταν το στάδιο της 
κακοήθειας. Ενδεικτικά αναφέρεται ότι η συγκέντρωση της καθεψίνης H ήταν υψηλότερη από την αντίστοιχη του μάρτυρα 
κατά 155% στο στάδιο Β1 και κατά 204,44% στο στάδιο D. Μεταξύ των δύο εξεταζόμενων πρωτεασών η καθεψίνη L έδειξε 
τη μεγαλύτερη αύξηση, η οποία στο στάδιο D ήταν 261,03% υψηλότερη από την αντίστοιχη του μάρτυρα-φυσιολογικού 
ιστού. Σύμφωνα με τα αποτελέσματα αυτά, οι μεταβολές της έκφρασης των κυστεϊνοπρωτεασών H και L των καρκινικών 
ιστών παχέος εντέρου θα μπορούσαν να διαδραματίσουν σημαντικό ρόλο στην διάγνωση και την εξέλιξη του καρκίνου του 
παχέος εντέρου.
Λέξεις κλειδιά: Καρκίνος παχέος εντέρου, Kαθεψίνη H, Καθεψίνη L.
Καθεψίνες H και L στον καρκίνο του παχέος εντέρου.
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